Efficacy of Cilostazol in Prevention of Peripheral Neuropathy

Mansoura University

Status and phase: Completed; Phase 2; Phase 1

Conditions: Breast Cancer; Peripheral Neuropathy

Treatments: Drug: Cilostazol; Drug: Placebo

Study type: Interventional

Funder types: Other

Identifiers

NCT05298696

2021-395

Details and patient eligibility

About

There are several mechanisms concerning pathophysiology of paclitaxel induced peripheral neuropathy. One of the main mechanisms is induction of Schwann cell dedifferentiation by paclitaxel. At the preclinical level, cilostazol potently inhibited paclitaxel-induced dedifferentiation of cultured Schwann cells, yet this positive effect have not been clinically investigated.

Enrollment: 71 patients

Sex: All

Ages: 18 to 80 years old

Volunteers: No Healthy Volunteers

Inclusion criteria

1. Breast cancer patients who will receive paclitaxel post-anthracycline therapy.
2. Eastern Cooperative Oncology Group (ECOG) performance status from 0 to 2.
3. Adequate bone marrow function (white blood count ≥4,000/mm3, platelet count≥100,000/mm3), liver function (serum total bilirubin <1.5 mg/dl), renal function (creatinine < 1.5 mg/dl).

Exclusion criteria

1. Patients with signs and symptoms of clinical neuropathy at baseline.
2. Patients with diabetes mellitus or alcoholic disease.
3. Patients receiving vitamin/ supplementation drugs that interfere with the study intervention.

Trial design

Primary purpose: Prevention

Allocation: Randomized

Interventional model: Parallel Assignment

Masking: Double Blind

---

71 participants in 2 patient groups, including a placebo group

Intervention

Active Comparator group

Description:

Cilostazol 100 mg twice daily for treatment period

Treatment:

Drug: Cilostazol

Control

Placebo Comparator group

Description:

placebo twice daily for treatment period

Treatment:

Drug: Placebo